obesity treatment

CVS will restore Zepbound coverage on October 1 and add Eli Lilly's newly approved Foundayo obesity pill to drug plans starting June 1. This expanded coverage could significantly increase market access for weight management medications.

Novo Nordisk raised its 2026 outlook following strong sales performance from its newly launched Wegovy pill, which exceeded forecasts. This demonstrates the pharmaceutical sector's ability to drive significant stock gains through successful product launches in high-demand therapeutic areas like obesity treatment.